BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34848180)

  • 1. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
    Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
    BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
    PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
    AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
    Beksinska M; Issema R; Beesham I; Lalbahadur T; Thomas K; Morrison C; Hofmeyr GJ; Steyn PS; Mugo N; Palanee-Phillips T; Ahmed K; Nair G; Baeten JM; Smit J
    EClinicalMedicine; 2021 Apr; 34():100800. PubMed ID: 33898953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
    Deese J; Chen PL; Gao X; Heffron R; Hobbs M; Lapple D; Jaspan H; Miller A; Nair G; Onono M; Palanee-Phillips T; Reddy K; Steiner MJ
    AIDS Behav; 2023 Mar; 27(3):978-983. PubMed ID: 36357806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
    Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
    Ryan R; Mussa A; Singtaa-Madliki M; Batting J; Balakrishna Y; Morroni C; Hofmeyr GJ
    Front Glob Womens Health; 2022; 3():887541. PubMed ID: 35669313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
    Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contraceptive Continuation and Experiences Obtaining Implant and IUD Removal Among Women Randomized to Use Injectable Contraception, Levonorgestrel Implant, and Copper IUD in South Africa and Zambia.
    Cartwright AF; Callahan RL; Beksinska M; Kasaro MP; Tang JH; Milford C; Wong C; Velarde M; Maphumulo V; Fawzy M; Chinyama M; Chabu E; Mudenda M; Smit J
    Stud Fam Plann; 2023 Jun; 54(2):379-401. PubMed ID: 36727169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception.
    Onono M; Nanda K; Heller KB; Taylor D; Yacobson I; Heffron R; Kasaro MP; Louw CE; Nhlabasti Z; Palanee-Phillips T; Smit J; Wakhungu I; Gichangi PB; Mugo NR; Morrison C; Baeten JM;
    Contracept X; 2020; 2():100026. PubMed ID: 32577615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF; Bunjun R; Dabee S; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Harryparsad R; Happel AU; Gamieldien H; Qumbelo Y; Sinkala M; Scoville CW; Heller K; Baeten JM; Bosinger SE; Burgener A; Heffron R; Jaspan HB; Passmore JAS
    J Infect Dis; 2022 Sep; 226(5):907-919. PubMed ID: 35263421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
    Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
    Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
    PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.